Sandoz Archives -

Events/ Reuters Pharma 2022/ Views and analysis

Reuters Pharma 2022 – a day one overview – part 1

Nicole Raleigh AI, Axtria, data, digital, diversity, ESG, Nice Acropolis, Palantir Technologies, patient engagement, pharma, Reuters Pharma, Sandoz, Sanofi, Teva 0 Comment

The Reuters Pharma event 2022 began as a bustling industry affair yesterday, based out of the Nice Acropolis

Reuters Pharma 2022 – a day one overview – part 1

https://pharmaphorum.com/events/reuters-pharma-2022-a-day-one-overview-part-1/

News/ News/ Sales and Marketing

Sandoz takes aim at Amgen’s Prolia/Xgeva with biosimilar

Phil Taylor Amgen, biosimilar, denosumab, Novartis, osteoporosis, Sandoz 0 Comment

Novartis’ soon-to-be-divested Sandoz unit has positive clinical trial data in hand for a biosimilar of Amgen’s blockbuster osteoporosis

Sandoz takes aim at Amgen’s Prolia/Xgeva with biosimilar

https://pharmaphorum.com/news/sandoz-takes-aim-at-amgens-prolia-xgeva-with-biosimilar/

News/ News/ Sales and Marketing

Novartis decides Sandoz’ future – and it’s a spin-out

Phil Taylor biosimilars, Financial, generics, M&A, Novartis, Sandoz 0 Comment

After months of deliberation, and no formal offers from a buyer, Novartis has decided that its generics business

Novartis decides Sandoz’ future – and it’s a spin-out

https://pharmaphorum.com/news/novartis-decides-sandoz-future-and-its-a-spin-out/

Podcast/ R&D/ Video/ Views & Analysis/ Views and analysis

Challenges and opportunities in the off-patent sector: the pharmaphorum podcast

Jonah Comstock biosimilars, COVID-19, generics, Rebecca Guntern, Sandoz 0 Comment

In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock welcomes Rebecca Guntern, vice president of medicines

Challenges and opportunities in the off-patent sector: the pharmaphorum podcast

https://pharmaphorum.com/r-d/challenges-and-opportunities-in-the-off-patent-sector/

News/ News/ Sales and Marketing

Novartis takes aim at MS blockbuster Tysabri in US and Europe

Phil Taylor Biogen, biosimilar, Novartis, Sandoz, Tysabri 0 Comment

Regulators in the US and Europe have started to review Novartis’ biosimilar version of Biogen’s big-selling multiple sclerosis

Novartis takes aim at MS blockbuster Tysabri in US and Europe

https://pharmaphorum.com/news/novartis-takes-aim-at-ms-blockbuster-tysabri-in-us-and-europe/

News/ News/ Sales and Marketing

Novartis faces tougher decision on Sandoz, as finances recover

Phil Taylor biosimilars, Financial, generics, M&A, Novartis, Sandoz 0 Comment

Novartis said this morning that it remains on course to make a decision on the future of its

Novartis faces tougher decision on Sandoz, as finances recover

https://pharmaphorum.com/news/novartis-faces-tougher-decision-on-sandoz-as-finances-recover/

News/ News/ Sales and Marketing

Polpharma in pole position for biosimilar Tysabri in Europe

Phil Taylor Biogen, biosimilar, Polpharma, Sandoz, Tysabri 0 Comment

Polpharma Biologics has become the first company to file for approval in the EU of a biosimilar version

Polpharma in pole position for biosimilar Tysabri in Europe

https://pharmaphorum.com/news/polpharma-in-pole-position-for-biosimilar-tysabri-in-europe/

News

Sandoz, Ares extend digital alliance on antimicrobial resistance

Phil Taylor antibiotic, antimicrobial resistance, Ares Genetics, generic, infectious disease, OpGen, Sandoz 0 Comment

Novartis’ generics unit Sandoz has moved on to the next stage of a collaboration with Ares Genetics, which

Sandoz, Ares extend digital alliance on antimicrobial resistance

https://pharmaphorum.com/news/sandoz-ares-extend-digital-alliance-on-antimicrobial-resistance/

News/ News/ Sales and Marketing

Sandoz bulks up ahead of possible sale with Coalesce buy

Phil Taylor generics, M&A, Novartis, respiratory, Sandoz 0 Comment

Novartis may be planning to sell off its generics business Sandoz, but that hasn’t stopped it investing in

Sandoz bulks up ahead of possible sale with Coalesce buy

https://pharmaphorum.com/news/sandoz-bulks-up-ahead-of-possible-sale-with-coalesce/

Trending

Sandoz

Login